Where to Obtain Polygenic Risk Scores for ASCVD
Polygenic risk scores (PRS) for atherosclerotic cardiovascular disease are not yet routinely available for clinical use, and the American College of Medical Genetics and Genomics (ACMG) currently states there is limited evidence to support using PRS to guide medical management. 1
Current Clinical Availability
The landscape for obtaining PRS for ASCVD is extremely limited:
Clinical laboratory testing: As of 2023, ACMG guidelines emphasize that PRS-based medical management should be evidence-based, but currently there is insufficient evidence to support routine clinical use 1. However, recent 2026 data indicates that integrated PRS are now becoming available as "clinically orderable tests" in some U.S. health systems 2.
Research programs: The most accessible route currently is through research biobanks like the All of Us Research Program or Mass General Brigham Biobank, though these are primarily research contexts rather than clinical services 2, 3.
Direct-to-consumer testing: While genetic profiling has become widespread in direct-to-consumer settings with "tens of millions of people" receiving results 4, the clinical validity and utility of these PRS reports remain questionable.
Critical Limitations You Must Understand
The ACMG explicitly states that a low PRS does not rule out significant disease risk 1. Key problems include:
Ancestry-dependent accuracy: Most PRS models are derived from populations of European descent, leading to decreased predictive accuracy in other populations due to differences in linkage disequilibrium patterns and allele frequencies 1. Performance varies substantially across genetic ancestry groups 3.
Not designed for symptomatic individuals: PRS have not been designed or tested for differential diagnosis in symptomatic individuals 5.
Population-level vs. individual prediction: PRS generate likelihood ratios that require accurate understanding of disease incidence in your specific population. The absolute lifetime risk may not be available 1.
Your Specific Clinical Context
Given your LDL-C of 140 mg/dL and Lp(a) of 120 nmol/L:
You already have established cardiovascular risk factors that warrant evidence-based management regardless of PRS results. Recent 2026 data shows that individuals with high genetic risk and moderate LDL-C elevations (like yours) have CAD risk comparable to or exceeding severe hypercholesterolemia (LDL-C ≥190 mg/dL) 6. However, this finding doesn't change the fact that your current lipid profile already indicates need for intervention.
The integrated PRS for hypercholesterolemia and elevated lipoprotein(a) show strong discrimination (OR 4.1 and 41.0 respectively for high vs. average genetic risk) 2, but ACMG guidelines state that clinical follow-up should be consistent with best practices outlined by professional societies regardless of PRS results 1.
Practical Recommendation
Do not delay evidence-based cardiovascular risk management while seeking PRS testing. Your elevated LDL-C and Lp(a) already warrant guideline-directed therapy. If you wish to pursue PRS:
- Ask your physician if your health system participates in research biobanks offering PRS (Mass General Brigham, All of Us Program participants)
- Inquire about emerging clinical PRS services, though availability remains extremely limited as of 2026
- Understand that any PRS result should be interpreted alongside—not instead of—traditional risk factors
The absence of PRS should not delay appropriate cardiovascular risk reduction strategies based on your current lipid profile.